SMMT Files 8-K Furnishing Q2 2025 Financial Results as Exhibit 99.1

Rhea-AI Filing Summary

Summit Therapeutics Inc. disclosed that it furnished a press release announcing its financial results and operational progress for the quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 to this Current Report and is incorporated by reference into Item 2.02.

The filing clarifies that the exhibit is being furnished, not filed, and therefore is not subject to Section 18 liability and is not automatically incorporated by reference into other Securities Act or Exchange Act filings except by specific reference. The company’s common stock trades under the ticker SMMT on The Nasdaq Stock Market.

Positive

• Press release furnished publicly announcing Q2 2025 financial results and operational progress (Exhibit 99.1).
• Disclosure follows standard SEC practice by furnishing the release and clarifying its non‑filed status under Section 18.
• SMMT common stock is listed on Nasdaq, confirming exchange registration for the company’s shares.

Negative

• No financial figures or operational metrics are included in the body of the 8-K; readers must consult Exhibit 99.1 for details.
• Filing provides limited incremental information beyond notice that a press release has been issued.
• No material transactions, governance changes, or other substantive disclosures are included in this filing.

Insights

Financial Analyst

Routine 8-K furnishing a Q2 press release; filing itself lacks financial detail, so limited investor impact.

The filing notifies investors that Summit furnished a press release with second-quarter results and operational updates, but the substantive financial details appear only in the referenced exhibit rather than inline in the 8-K text. As a result, this 8-K serves primarily as a logistics notice that the company has issued a results release; investors must review Exhibit 99.1 for metrics and performance drivers.

Corporate Governance Expert

Disclosure is standard and procedurally correct; limitation of "filed" status reduces statutory liabilities for the company.

The company follows common practice by furnishing the press release as Exhibit 99.1 and expressly stating it is not "filed" under Section 18. This preserves flexibility and limits certain legal exposures while still making operational and results information publicly available. The 8-K provides no governance changes or material agreements.

0001599298FALSE00015992982025-08-112025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 11, 2025

Summit Therapeutics Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware			001-36866			37-1979717
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
601 Brickell Key Drive, Suite 1000, Miami, FL						33131
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (305) 203-2034

Not applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class			Trading Symbol(s)			Name of Each Exchange on Which Registered
Common stock, $0.01 par value per share			SMMT			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02 as if fully set forth herein.

In accordance with General Instruction B.2 of Form 8-K, the information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number			Description
99.1			Press Release, dated August 11, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

			SUMMIT THERAPEUTICS INC.
Date: August 11, 2025			By:			/s/ Manmeet S. Soni
						Chief Operating Officer, Chief Financial Officer and Director
						(Principal Financial Officer)

FAQ

What did Summit Therapeutics (SMMT) report in this 8-K?

The company furnished a press release announcing financial results and operational progress for the quarter ended June 30, 2025; the release is Exhibit 99.1 to the Current Report.

Is the press release in this 8-K considered "filed" under Section 18?

No. The filing expressly states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to Section 18 liability.

Where can I find the actual financial results referenced in the 8-K for SMMT?

The detailed financial results and operational information are contained in Exhibit 99.1, the press release furnished with the Current Report.

Is Summit Therapeutics identified as an emerging growth company in this filing?

The filing indicates the emerging growth company checkbox is not selected.

On which exchange is Summit Therapeutics' common stock listed and what is the ticker?

The company’s common stock is registered on The Nasdaq Stock Market under the ticker SMMT.